Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz Ggmbh

Biontech Se

Agenus Inc.

Biontech Rna Pharmaceuticals Gmbh

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

John Christopher Castle

Ugur Sahin

Martin Löwer

Michael Koslowski

Sebastian Kreiter

Mustafa Diken

Tana Omokoko

Jan Diekmann

Bernhard Renard

Johannes Hendrikus De Graaf

Cedrik Britten

Martin Lower

Sebastian Boegel

Arbel David Tadmor

Daniel Lewis Levey

Martin LÖWER

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

Individualized vaccines for cancer

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Predicting immunogenicity of T cell epitopes

Provided are compositions useful as therapeutic vaccines (e.g., cancer vaccines), and methods of producing such compositions. The compositions disclosed herein generally employ a stress protein and at least one synthetic peptide, which may be a phosphopeptide or phosphopeptide mimetic, comprising a cancer-specific mutation present in a patient's cancer.

Vaccines for treatment and prevention of cancer

Growing community of inventors

Mainz, Germany

John Christopher Castle